F. Michael Yakes
About
In The Last Decade
F. Michael Yakes
20 papers receiving 5.7k citations
Hit Papers
Peers
Comparison fields: 5 of 131
- Molecular Biology 3.4k
- Oncology 2.3k
- Pulmonary and Respiratory Medicine 1.1k
- Cancer Research 679
- Radiology, Nuclear Medicine and Imaging 652
Countries citing papers authored by F. Michael Yakes
This map shows the geographic impact of F. Michael Yakes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Michael Yakes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Michael Yakes more than expected).
Fields of papers citing papers by F. Michael Yakes
This network shows the impact of papers produced by F. Michael Yakes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Michael Yakes. The network helps show where F. Michael Yakes may publish in the future.
Co-authorship network of co-authors of F. Michael Yakes
This figure shows the co-authorship network connecting the top 25 collaborators of F. Michael Yakes. A scholar is included among the top collaborators of F. Michael Yakes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Michael Yakes. F. Michael Yakes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Title | Journal | Authors | Indexed citations |
|---|---|---|---|---|
| 1 | Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083) | Journal of Medicinal Chemistry | Han-Jie Zhou, Jinhai Wang et al. | 146 |
| 2 | Abstract 951: CB-5083 is a novel first in class p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models | Cancer Research | Ronan Le Moigne, Steve Wong et al. | 1 |
| 3 | In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer | Thyroid | Frauke Bentzien, Yongchang Shi et al. | 102 |
| 4 | Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth breakdown → | Molecular Cancer Therapeutics | F. Michael Yakes, Jason Chen et al. | 1036 |
| 5 | Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases | Cancer Research | Fawn Qian, Stefan Engst et al. | 282 |
| 6 | Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors | Oncogene | Roberto Bianco, Incheol Shin et al. | 357 |
| 7 | HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer | Seminars in Oncology | Carlos L. Arteaga, Stacy L. Moulder et al. | 67 |
| 8 | Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. breakdown → | PubMed | F. Michael Yakes, Wichai Chinratanalab et al. | 506 |
| 9 | PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization breakdown → | Nature Medicine | Incheol Shin, F. Michael Yakes et al. | 642 |
| 10 | HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer | Seminars in Oncology | Carlos L. Arteaga, Stacy L. Moulder et al. | 45 |
| 11 | Mutations associated with base excision repair deficiency and methylation-induced genotoxic stress | Proceedings of the National Academy of Sciences | Robert W. Sobol, David E. Watson et al. | 76 |
| 12 | ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. | PubMed | Anne E.G. Lenferink, Dagmar Busse et al. | 156 |
| 13 | Cyclin-Dependent Kinase Inhibitor P27Kip1 Is Required for Mouse Mammary Gland Morphogenesis and Function | The Journal of Cell Biology | Rebecca S. Muraoka, Anne E.G. Lenferink et al. | 67 |
| 14 | Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. | PubMed | Stacy L. Moulder, F. Michael Yakes et al. | 465 |
| 15 | Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis. | PubMed | S. Bardhan, Barbara D. Wamil et al. | 10 |
| 16 | Tyrosine kinase inhibitors: Rationale, mechanisms of action, and implications for drug resistance | Seminars in Oncology | Dagmar Busse, F. Michael Yakes et al. | 1 |
| 17 | CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis. | PubMed | F. Michael Yakes, Barbara D. Wamil et al. | 13 |
| 18 | Hydrogen Peroxide– and Peroxynitrite-Induced Mitochondrial DNA Damage and Dysfunction in Vascular Endothelial and Smooth Muscle Cells | Circulation Research | Scott W. Ballinger, Cam Patterson et al. | 385 |
| 19 | Functional studies on the anti-pathoangiogenic properties of CM101 | Angiogenesis | Heping Yan, Clint E. Carter et al. | 11 |
| 20 | Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress breakdown → | Proceedings of the National Academy of Sciences | F. Michael Yakes, Bennett Van Houten | 1496 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.